Company intelligence / Profile preview

CellPraxis

Porto Alegre, Rio Grande do Sul, Brazil

Ownership: Private
Development stage: Phase 2

Overview

CellPraxis developed an autologous cell therapy product that has shown efficacy in treating chronic wounds such as venous leg ulcers. Published clinical results indicate improved healing rates compared to standard care. The company's technology involves harvesting a patient's own cells, processing them ex vivo, and reapplying them to promote tissue regeneration. Some peer-reviewed studies have reported positive outcomes with their approach.

Therapeutic areas: EndocrinologyCardiovascularDermatology
Modalities: Cell therapy
Industry: Biotech

Drug pipeline

2 assets

ExZCell

Preclinical

1 more asset in the full pipeline.

Request access →

Partnerships

Collaborations with academic hospitals/universities in Brazil

Beyond the preview

Go deeper on CellPraxis.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on CellPraxis.

Explore the full profile